Research Report and Overview on Cancer Biological Therapy Market, 2016-2026

Biological cancer therapies use the body’s immune system, either directly or indirectly, to fight cancer or to lessen the side effects that may be caused by some cancer treatments. It is also called biotherapy or biological response modifiers. Interferons and monoclonal antibodies are among the most promising biological approaches to cancer treatment. Biological therapy works by stimulating, boosting, restoring or acting like the body’s immune system response against cancer cells. Cancer is a leading cause of death worldwide. Factors that contribute to geographic differences in cancer occurrence include the prevalence of risk factors, the availability and use of diagnostic tests, variations in the age structure of the population, and the availability and quality of treatment. According to WHO, approximately 14 million new cases and 8.2 million cancer related deaths in 2012. Tobacco use is the most important risk factor for cancer causing around 20% of global cancer deaths and around 70% of global lung cancer deaths.

Cancer Biological Therapy Market: Drivers and Restraints

The factors such as growing prevalence of cancer, continuous patent expiry of cancer drugs, rising impact of biosimilars and increasing demand of biological and targeted drug therapies will drive the overall cancer biological therapy market. According to WHO, the number of new cancer cases is projected to rise 70% in the coming two decades, mainly due to increased use of tobacco and alcohol consumption. However, the threat of failure in treatment, the high cost of drug development, the adverse effects of cancer drug therapy, particularly chemotherapy and stricter government regulations will hinders the overall cancer biological therapy market growth globally.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-2044

Cancer Biological Therapy Market: Segmentation

The global Cancer Biological Therapymarket is classified on the basis of Product type, distribution channels and regional presence.

Segmentation based on product type:

Vaccines

Cancer growth blockers

Tyrosine kinase inhibitors

Proteasome inhibitors

mTOR inhibitors

Monoclonal antibodies

Naked monoclonal antibodies

Conjugated monoclonal antibodies

Bispecific monoclonal antibodies

Cytokines

Interferons

Interleukins

Blood cell growth factors

Lenograstim

Filgrastim

Gene therapy

Segmentation based on distribution channels:

Hospital pharmacies

Retail pharmacies

Mail order pharmacies

Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-2044

Cancer Biological Therapy Market: Overview

The immune system protects a person from infection and disease. The Biological therapies are used to lessen the spread and lower the risk of recurrence for some cancers, slow the growth, control symptoms of cancer, deliver radioactive substances or chemotherapy drugs directly to a tumour lessen and some of the side effects from cancer treatments. Immune system recognize antigens on the surface of viruses, bacteria, other germs and cancer cells. Antigens mark these cells as being different (foreign) so the immune system can find them. The immune system reacts to these antigens and destroys the cells they are attached to. According to Globocan, in economically developed countries, 58% of all newly diagnosed cancer cases occur at 65 years of age and older, compared with 40% in developing countries. When countries are grouped according to income, cancer is the second leading cause of death in high-income countries and the third leading cause of death in low- and middle-income countries. Among females, the most common cancer sites were either breast or cervical cancer, with the exceptions of South Korea (thyroid), Mongolia and Laos (liver) and China and North Korea (lung).

Cancer Biological Therapy Market: Regional Overview

Geographically, the market is dominated by North America, followed by Europe, Asia Pacific. Growth in the North American segment is primarily driven by presence of large number of cancer biological drug and vaccine manufacturers, increasing disposable income, affordable cancer treatment facility and growing number of health insurance coverage for life-threatening diseases. According to National Cancer Institute (NCI) an estimated 16, 85,210 new cases will be diagnosed in 2016, in the US. Europe is the second largest market .Asia pacific is expected to grow at a highest rate due to increasing prevalence of cancer patient, better healthcare facilities and growing number of insurance coverage. Japan contributes largest share in cancer treatment market in Asia Pacific due to high prevalence of cancer in Japanese population.

Speak To Analyst@ http://www.futuremarketinsights.com/askus/rep-gb-2044

Cancer Biological Therapy Market: Key Players

Some of the major players operating in the market for Cancer Biological Therapy Market are F. Hoffmann-La Roche AG, Novartis International AG, Merck & Co., Inc., Amgen Inc., GlaxoSmithKline Plc, Bristol-Myers Squibb, Eli Lilly, Spectrum Pharmaceuticals, Inc., Seattle Genetics, Inc., Celgene Corporation and others

About Us:
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.

Contact Us:
Future Market Insights
616 Corporate Way,
Suite 2-9018,
Valley Cottage,
New York 10989,
United States
Tel: +1-347-918-3531
Fax: +1-845-579-5705
Email: sales@futuremarketinsights.com
Press: press@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.